Bridging the gap between science and business
Dr. Peter French is a leader in the Australian biotechnology industry with more than 40 years’ experience in both academic and commercial executive roles in the life sciences industry.
Dr French brings his rare combination of academic and commercial experience to each project. Not only can he do a deep dive into the science to examine the strengths and weaknesses of a potential technology, but he can also review the potential commerciality of the organisation’s business case.
His qualifications and work experience over the past 40 years support this duality of expertise. He holds both a PhD in cell and molecular biology and an MBA in Technology Management. He has conducted research in a range of fields including neuroscience, cell biology of cancer, immunology and inflammation, infectious disease, diagnostic assay development, in vitro imaging, gene therapy and clinical trials.
In the biotechnology industry, he has founded or co-founded several ASX-listed and private companies, (see 'The Role of Serendipity In Biotechnology Start Up Companies') and has listed one company on the NASDAQ. He has raised around $100M in funding from US and Australian investors to support the development of early stage Australian life sciences companies. He is an experienced Director, having served on several public company Boards in Australia.
On the science or technology under consideration.
Utilising my extensive Australian biotechnology and healthcare network to connect organisations
Advice on capital raising approaches in the US and Australia
Advice and assistance for early and mid-career professionals in the life sciences field.
DO'S AND DON'TS OF SUCCESSFUL DRUG DEVELOPMENT
REFLECTIONS OF TWO BIOTECH VETERANS
DR PETER FRENCH & DR KEVIN LYNCH
"Gaining approval for a new drug product takes an average of 10–15 years of research and development and
costs on average around U.S. $1.3 billion1. Despite these significant investments in time and money, 88% of
drug candidates in clinical trials fail. It is a high-risk game.
After a combined 60 years working in this area and witnessing a few major successes but many more failures, the two authors here review some key areas to consider when a biotech company sets out on the drug development journey..."